Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707868 | 0.81 | NPC1 (0.55) | NPC1RAB9ACA12CA1CA9 | |
| SCHEMBL28568187 | 0.78 | RAB9A (0.49) | NPC1RAB9AMAPTKDM4EMEN1 | |
| SCHEMBL9418052 | 0.78 | NPC1 (0.49) | NPC1RAB9AMAPTKDM4EMEN1 | |
| SCHEMBL7382792 | 0.77 | NPC1 (0.42) | NPC1RAB9ACA12CA1CA9 | |
| SCHEMBL7315076 | 0.76 | NPC1 (0.63) | NPC1RAB9AMAPTKDM4EMEN1 | |
| SCHEMBL11715245 | 0.75 | NPC1 (0.46) | NPC1RAB9AMAPTKDM4EMEN1 | |
| SCHEMBL28882874 | 0.75 | NPC1 (0.61) | NPC1RAB9AMAPTKDM4EMEN1 | |
| Benzene SCHEMBL6030702 | 0.75 | MAPT (0.61) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4464271 | 0.74 | ELANE (0.64) | MEN1KMT2A | |
| SCHEMBL11062174 | 0.74 | TDP1 (0.50) | NPC1RAB9AMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
| EP-1122245-B1 | 2-Amino-benzoxazinones for the treatment of viral infections | SEARLE & CO (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| EP-1210088-A4 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | SEARLE & CO (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| EP-1210088-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001003697-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS | G.D. SEARLE & CO. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | NPC1 2233/4885RAB9A 1233/4885CA12 3354/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | NPC1 2840/4885RAB9A 2034/4885CA12 3435/4885 |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | NPC1 3535/4885RAB9A 4106/4885CA12 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.